Lets beat cancer!!

1
1
Favorite

A79
2021-07-28

Lets beat cancer!!

TYME Stock: The Cancer Treatment News That’s Boosting Tyme Today

While the focus for most of last week and today has been centered around cryptocurrency and public o

TYME Stock: The Cancer Treatment News That’s Boosting Tyme Today

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

Top
Latest

A79
·2021-11-23
Yea
Reply
1
Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":803108237,"tweetId":"803108237","gmtCreate":1627426634429,"gmtModify":1703489542826,"author":{"id":3580565594783380,"authorId":3580565594783380,"authorIdStr":"3580565594783380","name":"A79","avatar":"https://static.tigerbbs.com/e27267c412cea01bdd4a47d746ba7606","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[],"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Lets beat cancer!!</p></body></html>","htmlText":"<html><head></head><body><p>Lets beat cancer!!</p></body></html>","text":"Lets beat cancer!!","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/803108237","repostId":1123658607,"repostType":2,"repost":{"id":"1123658607","pubTimestamp":1627347222,"share":"https://www.laohu8.com/m/news/1123658607?lang=&edition=full","pubTime":"2021-07-27 08:53","market":"us","language":"en","title":"TYME Stock: The Cancer Treatment News That’s Boosting Tyme Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1123658607","media":"investorplace","summary":"While the focus for most of last week and today has been centered around cryptocurrency and public o","content":"<p>While the focus for most of last week and today has been centered around cryptocurrency and public offerings, biotech companies have been quietly making a killing. New deals, patents, expansions and clinical trial results have been pushing a great deal of medical stocks upward at impressive rates. Joining the ranks of big gainers today is&nbsp;<b>Tyme Technologies</b>(NASDAQ:<b><u>TYME</u></b>). Thanks to the announcement of a patent approval, TYME stock is soaring quite high.</p>\n<p>Tyme is a Bedminster, New Jersey-based, small cap biotech outfit. The company develops cancer metabolism-based therapies, or CMBTs, which take advantage of cancer cells’ differing metabolic functions to kill them. The company is announcing today some great news in the form of apatent approval. The patent will protect Tyme’s development of its CMBT treatment product.</p>\n<p>The company’s CMBT therapy is an oral therapy that combines tyrosine with a therapeutic agent. In essence, tyrosine is one of the non-essential amino acids on which cancer cells feverishly consume. Cancer cells need far more of these compounds because they don’t produce enough of their own. Since cancer cells metabolize far greater amounts of these non-essential components than the average cell, the therapeutic agent is more easily introduced to these cells. The agent then kills the cell.</p>\n<p>TYME Stock Soars on Patent News</p>\n<p>According to Tyme’s CSO, Steve Hoffman, the company plans to move forward with the development of the therapy in a way that is even safer and more effective than its current formula. All in all, this news is great for investors; with a patent secured, and an already promising initial product in the books, there are further growth prospects for TYME stock, which will attract new investors.</p>\n<p>The news is already paying off nicely for TYME. The stock is up over 72% on the news, and volume is massively increasing. 214 million shares of TYME are changing hands today, far greater than the average 2.7 million.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TYME Stock: The Cancer Treatment News That’s Boosting Tyme Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTYME Stock: The Cancer Treatment News That’s Boosting Tyme Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 08:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/07/tyme-stock-the-cancer-treatment-news-thats-boosting-tyme-today/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While the focus for most of last week and today has been centered around cryptocurrency and public offerings, biotech companies have been quietly making a killing. New deals, patents, expansions and ...</p>\n\n<a href=\"https://investorplace.com/2021/07/tyme-stock-the-cancer-treatment-news-thats-boosting-tyme-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TYME":"Tyme Technologies, Inc."},"source_url":"https://investorplace.com/2021/07/tyme-stock-the-cancer-treatment-news-thats-boosting-tyme-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123658607","content_text":"While the focus for most of last week and today has been centered around cryptocurrency and public offerings, biotech companies have been quietly making a killing. New deals, patents, expansions and clinical trial results have been pushing a great deal of medical stocks upward at impressive rates. Joining the ranks of big gainers today is Tyme Technologies(NASDAQ:TYME). Thanks to the announcement of a patent approval, TYME stock is soaring quite high.\nTyme is a Bedminster, New Jersey-based, small cap biotech outfit. The company develops cancer metabolism-based therapies, or CMBTs, which take advantage of cancer cells’ differing metabolic functions to kill them. The company is announcing today some great news in the form of apatent approval. The patent will protect Tyme’s development of its CMBT treatment product.\nThe company’s CMBT therapy is an oral therapy that combines tyrosine with a therapeutic agent. In essence, tyrosine is one of the non-essential amino acids on which cancer cells feverishly consume. Cancer cells need far more of these compounds because they don’t produce enough of their own. Since cancer cells metabolize far greater amounts of these non-essential components than the average cell, the therapeutic agent is more easily introduced to these cells. The agent then kills the cell.\nTYME Stock Soars on Patent News\nAccording to Tyme’s CSO, Steve Hoffman, the company plans to move forward with the development of the therapy in a way that is even safer and more effective than its current formula. All in all, this news is great for investors; with a patent secured, and an already promising initial product in the books, there are further growth prospects for TYME stock, which will attract new investors.\nThe news is already paying off nicely for TYME. The stock is up over 72% on the news, and volume is massively increasing. 214 million shares of TYME are changing hands today, far greater than the average 2.7 million.","news_type":1},"isVote":1,"tweetType":1,"viewCount":828,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ORIG"},"commentList":[{"id":6683394,"gmtCreate":1637618025531,"gmtModify":1663237395226,"authorId":3580565594783380,"author":{"id":3580565594783380,"authorId":3580565594783380,"name":"A79","avatar":"https://static.tigerbbs.com/e27267c412cea01bdd4a47d746ba7606","vip":1,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":803108237,"type":1,"supId":0,"prevId":0,"content":"Yea","text":"Yea","html":"Yea","likeSize":1,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"invalid","coins":0,"score":0}],"hasMoreComment":true,"orderType":2}